Show simple item record

dc.contributor.authorPilskog, Martin
dc.contributor.authorBeisland, Christian
dc.contributor.authorAkslen, Lars A
dc.contributor.authorBostad, Leif
dc.contributor.authorHaug, Åse
dc.contributor.authorHeinrich, Daniel
dc.contributor.authorHjelle, Karin Margrethe
dc.contributor.authorStraume, Oddbjørn
dc.date.accessioned2019-07-12T12:08:41Z
dc.date.available2019-07-12T12:08:41Z
dc.date.issued2017-08-31
dc.identifier.citationPilskog, M., Beisland, C., Akslen, L. A., Bostad, L., Haug, Å., Heinrich, D., ... & Straume, O. (2017). Predictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinoma. BMC urology, 17(1), 74.en
dc.identifier.issn1471-2490
dc.identifier.urihttps://hdl.handle.net/10642/7292
dc.description.abstractBackground Sunitinib has become mainstay first line treatment for patients with metastatic renal clear cell carcinoma (mRCC). Still, useful predictive markers of response are lacking and urgently needed for clinical decision making. Methods In the present study we investigated the predictive value of standard serum markers as well as clinical markers, including C-reactive protein (CRP), Neutrophil to Lymphocyte ratio (NLR) and early hypertension (eHTN) in an unselected prospective patient population treated with sunitinib for mRCC. Forty-six patients were enrolled in a prospective single-arm study of predictive markers for sunitinib response. Response rates according to RECIST 1.1 were used as primary end-point. Secondary objectives were to evaluate prognostic value of the candidate markers with regard to progression free survival (PFS) and overall survival (OS). In addition, toxicity rates and quality of life was recorded. Results Median PFS and OS was 9.1 months and 15.0 months, respectively. Of 38 patients evaluable for response, 1 patient had complete response (CR), 7 had partial response (PR), 18 had stable disease (SD) and 12 had progressive disease (PD). Normal CRP at baseline was significantly associated with objective response (CR + PR) (p = 0.01). Normal CRP was also significantly associated with improved PFS and OS (Log rank, p = 0.05 and <0.01, respectively). Early hypertension, NLR and IMDC risk score were not significantly associated with response rates or survival. Conclusion Baseline CRP was a significant predictive factor of sunitinib response and a prognostic factor of survival. Baseline CRP might be a useful biomarker in the treatment planning of mRCC. Due to the relatively small sample size, our results need to be confirmed in larger studies.en
dc.language.isoenen
dc.publisherBMC Springeren
dc.relation.ispartofseriesBMC Urology;17(1)
dc.rightsAttribution 3.0 United States This is an open access article, originally published at https://doi.org/10.1186/s12894-017-0267-6en
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.subjectArtikkelen
dc.subjectVDP::Medisinske Fag: 700en
dc.titlePredictive value of C-reactive protein in patients treated with sunitinib for metastatic clear cell renal cell carcinomaen
dc.typeJournal articleen
dc.typePeer revieweden
dc.description.versionpublishedVersionen
dc.identifier.doihttps://doi.org/10.1186/s12894-017-0267-6
dc.identifier.cristinID1508673


Files in this item

Thumbnail
Thumbnail

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
This is an open access article, originally published at https://doi.org/10.1186/s12894-017-0267-6
Except where otherwise noted, this item's license is described as Attribution 3.0 United States This is an open access article, originally published at https://doi.org/10.1186/s12894-017-0267-6